UNDERWRITING AGREEMENTUnderwriting Agreement • April 8th, 2021 • Harrow Health, Inc. • Pharmaceutical preparations • New York
Harrow Health, Inc., a Delaware corporation (the “Selling Stockholder”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to sell to National Securities Corporation (the “Underwriter”), an aggregate of 1,320,000 issued and outstanding shares (the “Firm Shares”) and, at the election of the Underwriter, up to 198,000 additional shares (the “Additional Shares”), in each case of common stock, par value $0.001 per share (the “Common Stock”) of Eton Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in an offering under the Company’s registration statement on Form S-3 (File No. 333-240252) (the Firm Shares and the Additional Shares being collectively called the “Shares”).
